Inactive Instrument

Analyst Reco. Orchard Therapeutics plc

Equities

ORTX

US68570P2002

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cantor Fitzgerald Downgrades Orchard Therapeutics to Neutral From Overweight, Raises Price Target to $16 From $15	05/23/05	MT
Stifel Downgrades Orchard Therapeutics to Hold From Buy, Cuts Price Target to $16 From $22	05/23/05	MT
Oppenheimer Adjusts Orchard Therapeutics Price Target to $34 From $37, Maintains Outperform Rating	13/23/13	MT
Cantor Fitzgerald Adjusts Orchard Therapeutics' Price Target to $15 From $3, Keeps Overweight Rating	28/23/28	MT
Oppenheimer Adjusts Orchard Therapeutics Price Target to $37 From $5, Maintains Outperform Rating	13/23/13	MT
Barclays Lowers Orchard Therapeutics' Price Target to $4 From $6, Maintains Overweight Rating	13/22/13	MT
Cantor Fitzgerald Lowers Price Target for Orchard Therapeutics to $5 From $9, Maintains Overweight Rating	01/22/01	MT
Stifel Lowers Price Target for Orchard Therapeutics to $5 From $12, Maintains Buy Rating	01/22/01	MT
SMBC Nikko Downgrades Orchard Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $8	01/22/01	MT
Cowen Downgrades Orchard Therapeutics to Market Perform From Outperform	31/22/31	MT
Cantor Fitzgerald Assumes Coverage on Orchard Therapeutics With Overweight Rating, $9 Price Target	29/21/29	MT
JPMorgan Downgrades Orchard Therapeutics to Underweight From Neutral	16/21/16	MT
Wedbush Adjusts Price Target for Orchard Therapeutics to $11 From $13, Maintains Outperform Rating	06/21/06	MT
Oppenheimer Adjusts Orchard Therapeutics PT to $13 From $15, Maintains Outperform Rating	05/21/05	MT
ORCHARD THERAPEUTICS : JPMorgan Downgrades Orchard Therapeutics to Neutral From Overweight	18/21/18	MT
ORCHARD THERAPEUTICS : Goldman Sachs Adjusts Orchard Therapeutics PT to $10 From $13, Maintains Buy Rating	30/21/30	MT
ORCHARD THERAPEUTICS : SMBC Nikko Adjusts Orchard Therapeutics PT to $16 From $19, Maintains Outperform Rating	30/21/30	MT
ORCHARD THERAPEUTICS : Cantor Fitzgerald Adjusts Orchard Therapeutics' Price Target to $12 From $17, Reiterates Overweight Rating	30/21/30	MT
ORCHARD THERAPEUTICS : JPMorgan Adjusts Orchard Therapeutics' Price Target to $14 From $15, Reiterates Overweight Rating	30/21/30	MT
ANALYST RECOMMENDATIONS : Apple, FedEx, Intellia Therapeutics, Reckitt Benckiser, XPO Logistics...	30/21/30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Orchard Therapeutics plc

Equities

ORTX

US68570P2002

Analyst Reco.

Filters